Previous 10 | Next 10 |
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD...
Topline data expected in June 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ...
2023-03-16 10:08:56 ET Alzamend Neuro press release ( NASDAQ: ALZN ): Q3 GAAP EPS of -$0.06. At January 31, 2023, cash was $7.4 million, and working capital was $5.8 million. Net cash used in operations was $6.7 million during the nine months ended January 31, 2023. ...
Company had $7.4 Million Cash at January 31, 2023 Additional Non-Dilutive Capital via Note Receivable of $14.8 Million Expected in December 2023 Initiation of Phase I/IIA Clinical Trial for ALZN002 to Treat Mild to Moderate Dementia of the Alzheimer’s Type Expected ...
Presentation on Thursday, February 2, 2023 at 10:30 a.m. ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer...
Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clini...
Alzamend Neuro ( NASDAQ: ALZN ) said on Wednesday that it expects topline data from a Phase IIA trial for AL001 treatment of dementia related to Alzheimer’s in second quarter of 2023. The company also said it was partnering with the Miller School of Medicine, Inte...
Topline Data for Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s Expected in Second Quarter of 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical compan...
NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Alzamend Neuro. Toni had the pleasure of recently conducti...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...